Anti-baff-anti-il-17 bispecific antibodies
AssigneeEli Lilly and Company
InventorsBarrett Allan, Robert Jan Benschop, Jirong Lu
Life of this patent
Estimating the term…
Abstract
Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM).
Claims21
A bispecific antibody comprising two first polypeptides and two second polypeptides wherein the amino acid sequence of the first polypeptide is SEQ ID NO:1 and the amino acid sequence of the second polypeptide is SEQ ID NO:2.
A DNA molecule comprising a polynucleotide sequence encoding a polypeptide having the amino acid sequence of SEQ ID NO:1.
A DNA molecule comprising a polynucleotide sequence encoding a polypeptide having the amino acid sequence of SEQ ID NO:2.
A DNA molecule comprising a polynucleotide sequence encoding a polypeptide having the amino acid sequence of SEQ ID NO:1 and comprising a polynucleotide sequence encoding a polypeptide having the amino acid sequence of SEQ ID NO:2.
A mammalian cell comprising a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO:1 and a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO:2, which cell is capable of expressing a bispecific antibody comprising a first polypeptide having an amino acid sequence of SEQ ID NO:1 and a second polypeptide having an amino acid sequence of SEQ ID NO:2.
Dependencies are inferred from the claim text.